NASDAQ:IBB - Ishares Nasdaq Biotechnology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$107.56 +0.22 (+0.20 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$107.56
Today's Range$107.26 - $107.7795
52-Week Range$94.20 - $119.30
Volume2.06 million shs
Average Volume2.89 million shs
Market Capitalization$8.81 billion
P/E RatioN/A
Dividend Yield0.39%
Beta1.34

About Ishares Nasdaq Biotechnology (NASDAQ:IBB)

Ishares Nasdaq Biotechnology logoiShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Receive IBB News and Ratings via Email

Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Blackrock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$8.90 billion
Average Daily Volume$2.74 million
Discount/Premium-1.41%

ETF Expenses

Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of Ishares Nasdaq Biotechnology (NASDAQ:IBB)
Currency Exposure of Ishares Nasdaq Biotechnology (NASDAQ:IBB)
Sector Exposure of Ishares Nasdaq Biotechnology (NASDAQ:IBB)
Industry Exposure of Ishares Nasdaq Biotechnology (NASDAQ:IBB)

Ishares Nasdaq Biotechnology (NASDAQ:IBB) Frequently Asked Questions

What is Ishares Nasdaq Biotechnology's stock symbol?

Ishares Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "IBB."

How often does Ishares Nasdaq Biotechnology pay dividends? What is the dividend yield for Ishares Nasdaq Biotechnology?

Ishares Nasdaq Biotechnology announced a quarterly dividend on Thursday, December 21st. Stockholders of record on Friday, December 22nd will be paid a dividend of $0.125 per share on Thursday, December 28th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Thursday, December 21st. This is a positive change from Ishares Nasdaq Biotechnology's previous quarterly dividend of $0.04. View Ishares Nasdaq Biotechnology's Dividend History.

When did Ishares Nasdaq Biotechnology's stock split? How did Ishares Nasdaq Biotechnology's stock split work?

Ishares Nasdaq Biotechnology's stock split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly issued shares were distributed to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of Ishares Nasdaq Biotechnology stock prior to the split would have 300 shares after the split.

Who are some of Ishares Nasdaq Biotechnology's key competitors?

Who are Ishares Nasdaq Biotechnology's key executives?

Ishares Nasdaq Biotechnology's management team includes the folowing people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
  • Michael Arthur Latham, President, Trustee
  • Jack Gee, Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • , Bio & Compensation - 
  • Amy Schioldager, Executive Vice President
  • Ira P. Shapiro, Vice President, Chief Legal Officer
  • Matt Tucker, Vice President
  • , Bio & Compensation - 
  • Eilleen M. Clavere, Secretary
  • Cecilia H. Herbert, Independent Trustee
  • Charles A. Hurty, Independent Trustee

Has Ishares Nasdaq Biotechnology been receiving favorable news coverage?

Media stories about IBB stock have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ishares Nasdaq Biotechnology earned a daily sentiment score of 0.18 on Accern's scale. They also assigned media stories about the financial services provider an impact score of 47.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Ishares Nasdaq Biotechnology's major shareholders?

Ishares Nasdaq Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Natixis (1.38%), Royal Bank of Canada (1.07%), Commerce Bank (0.97%), Clal Insurance Enterprises Holdings Ltd (0.91%), PNC Financial Services Group Inc. (0.79%) and LPL Financial LLC (0.61%). View Institutional Ownership Trends for Ishares Nasdaq Biotechnology.

Which major investors are selling Ishares Nasdaq Biotechnology stock?

IBB stock was sold by a variety of institutional investors in the last quarter, including Clal Insurance Enterprises Holdings Ltd, Psagot Investment House Ltd., BB&T Securities LLC, NF Trinity Capital Hong Kong Ltd, The Manufacturers Life Insurance Company , PNC Financial Services Group Inc., Blair William & Co. IL and Analyst IMS Investment Management Services Ltd.. View Insider Buying and Selling for Ishares Nasdaq Biotechnology.

Which major investors are buying Ishares Nasdaq Biotechnology stock?

IBB stock was bought by a variety of institutional investors in the last quarter, including Natixis, State of Tennessee Treasury Department, First Republic Investment Management Inc., Commerzbank Aktiengesellschaft FI, LPL Financial LLC, Graham Capital Management L.P., Cheyne Capital Management UK LLP and Timber Hill LLC. View Insider Buying and Selling for Ishares Nasdaq Biotechnology.

How do I buy shares of Ishares Nasdaq Biotechnology?

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ishares Nasdaq Biotechnology's stock price today?

One share of IBB stock can currently be purchased for approximately $107.56.

How big of a company is Ishares Nasdaq Biotechnology?

Ishares Nasdaq Biotechnology has a market capitalization of $8.81 billion.


MarketBeat Community Rating for Ishares Nasdaq Biotechnology (IBB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Ishares Nasdaq Biotechnology and other stocks. Vote "Outperform" if you believe IBB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ishares Nasdaq Biotechnology (NASDAQ:IBB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Ishares Nasdaq Biotechnology (NASDAQ:IBB) Consensus Price Target History

Price Target History for Ishares Nasdaq Biotechnology (NASDAQ:IBB)
Show:

Earnings

Dividends

Ishares Nasdaq Biotechnology (NASDAQ:IBB) Dividend Information

Ishares Nasdaq Biotechnology pays an annual dividend of $0.42 per share, with a dividend yield of 0.39%. IBB's most recent quarterly dividend payment was Thursday, December 28.
Most Recent Dividend:12/28/2017
Annual Dividend:$0.42
Dividend Yield:0.39%
Payout Ratio(s):N/A
Dividend Payments by Quarter for Ishares Nasdaq Biotechnology (NASDAQ:IBB)

Ishares Nasdaq Biotechnology (NASDAQ:IBB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/21/2017Quarterly$0.12500.47%12/21/201712/22/201712/28/2017
9/26/2017Quarterly$0.03970.14%9/26/20179/27/20179/29/2017
6/27/2017quarterly$0.05890.23%6/27/20176/29/20176/30/2017
3/24/2017quarterly$0.09970.41%3/24/20173/28/20173/30/2017
12/22/2016quarterly$0.03060.14%12/22/201612/27/201612/29/2016
6/24/2015quarterly$0.01930.06%6/24/20156/26/20156/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Headlines

Ishares Nasdaq Biotechnology (NASDAQ IBB) News Headlines

Source:
DateHeadline
Analyzing Ishares Nasdaq Biotechnology (IBB) and GSV Capital (GSVC)Analyzing Ishares Nasdaq Biotechnology (IBB) and GSV Capital (GSVC)
www.americanbankingnews.com - May 23 at 5:16 PM
IBB, BIIB, CELG, VRTX: ETF Outflow AlertIBB, BIIB, CELG, VRTX: ETF Outflow Alert
www.nasdaq.com - May 23 at 8:09 AM
Rounds Report: Eiger Rallied While Sesen Bio Posted The Strong Interim Data For VISTARounds Report: Eiger Rallied While Sesen Bio Posted The Strong Interim Data For VISTA
seekingalpha.com - May 23 at 8:09 AM
In The Spotlight: Novus TherapeuticsIn The Spotlight: Novus Therapeutics
www.nasdaq.com - May 23 at 8:09 AM
Critical Comparison: Ishares Nasdaq Biotechnology (IBB) versus Hercules Technology Growth Capital (HTGC)Critical Comparison: Ishares Nasdaq Biotechnology (IBB) versus Hercules Technology Growth Capital (HTGC)
www.americanbankingnews.com - May 20 at 9:08 PM
Ishares Nasdaq Biotechnology (IBB) vs. Goldman Sachs BDC (GSBD) Financial ContrastIshares Nasdaq Biotechnology (IBB) vs. Goldman Sachs BDC (GSBD) Financial Contrast
www.americanbankingnews.com - May 19 at 9:21 PM
Rounds Report: The Eleven Train Is Increasing Speed Toward Its May 21 Clinical BinaryRounds Report: The Eleven Train Is Increasing Speed Toward Its May 21 Clinical Binary
seekingalpha.com - May 18 at 8:11 AM
Rounds Report: Eiger Moved Northbound While Spectrum Rallied Strongly Due To ADVANCE Trial ResultsRounds Report: Eiger Moved Northbound While Spectrum Rallied Strongly Due To ADVANCE Trial Results
seekingalpha.com - May 18 at 8:11 AM
On The Move: Viking TherapeuticsOn The Move: Viking Therapeutics
seekingalpha.com - May 18 at 8:11 AM
5 Top Stock Trades for Monday Morning5 Top Stock Trades for Monday Morning
finance.yahoo.com - May 15 at 8:10 AM
In The Spotlight: EvolusIn The Spotlight: Evolus
www.nasdaq.com - May 9 at 8:05 AM
3 Top Biotech Stocks to Buy in May3 Top Biotech Stocks to Buy in May
www.nasdaq.com - May 9 at 8:05 AM
iShares Nasdaq Biotechnology ETF (IBB) & Solectron (SLRC) Head-To-Head ComparisoniShares Nasdaq Biotechnology ETF (IBB) & Solectron (SLRC) Head-To-Head Comparison
www.americanbankingnews.com - May 5 at 9:46 PM
Biotech Stocks Set to BreakoutBiotech Stocks Set to Breakout
finance.yahoo.com - May 4 at 5:47 PM
Why Biogens Stock Rebound Is Good News for BiotechsWhy Biogen's Stock Rebound Is Good News for Biotechs
finance.yahoo.com - April 25 at 8:06 AM
WhiteHorse Finance (WHF) and iShares Nasdaq Biotechnology ETF (IBB) Head-To-Head ComparisonWhiteHorse Finance (WHF) and iShares Nasdaq Biotechnology ETF (IBB) Head-To-Head Comparison
www.americanbankingnews.com - April 20 at 11:16 PM
iShares Nasdaq Biotechnology ETF (IBB) & MVC Capital (MVC) Financial ReviewiShares Nasdaq Biotechnology ETF (IBB) & MVC Capital (MVC) Financial Review
www.americanbankingnews.com - April 20 at 9:38 PM
4 Beaten-Down Funds Set to Soar (with dividends up to 10.9%)4 Beaten-Down Funds Set to Soar (with dividends up to 10.9%)
www.nasdaq.com - April 20 at 5:32 PM
No Bid Coming for Shire ReportedlyNo Bid Coming for Shire Reportedly
finance.yahoo.com - April 19 at 5:52 PM
Could Big Biotech Earnings Be a Bust?Could Big Biotech Earnings Be a Bust?
www.barrons.com - April 18 at 5:56 PM
Biotech Sector Could See New LifeBiotech Sector Could See New Life
finance.yahoo.com - April 4 at 4:26 PM
Alkermes gets refusal letter from FDA regarding NDA for depression treatment; shares haltedAlkermes gets 'refusal' letter from FDA regarding NDA for depression treatment; shares halted
www.marketwatch.com - April 2 at 8:11 AM
Bank Loan Data Suggests The Top Is InBank Loan Data Suggests The Top Is In
seekingalpha.com - March 30 at 8:06 AM
Incyte’s Jakafi in 2017Incyte’s Jakafi in 2017
finance.yahoo.com - March 26 at 8:08 AM
RSI Alert: Celgene (CELG) Now OversoldRSI Alert: Celgene (CELG) Now Oversold
www.nasdaq.com - March 24 at 5:26 PM
Cramers charts show signs of life for the struggling biotech sectorCramer's charts show 'signs of life' for the struggling biotech sector
www.cnbc.com - March 22 at 5:48 PM
In The Spotlight: G1 Therapeutics - NasdaqIn The Spotlight: G1 Therapeutics - Nasdaq
www.nasdaq.com - March 22 at 8:10 AM
New Opportunities in Biotech: Cramers Off the Charts - TheStreet.comNew Opportunities in Biotech: Cramer's 'Off the Charts' - TheStreet.com
www.thestreet.com - March 22 at 8:10 AM
Tocagen Drug Candidate Looks Undervalued, But Very RiskyTocagen Drug Candidate Looks Undervalued, But Very Risky
seekingalpha.com - March 21 at 5:50 PM
Chopping a Way Back for the Bull: Cramers Mad Money Recap ... - TheStreet.comChopping a Way Back for the Bull: Cramer's 'Mad Money' Recap ... - TheStreet.com
www.thestreet.com - March 21 at 8:22 AM
Cramer's charts show 'signs of life' for the struggling b...Cramer's charts show 'signs of life' for the struggling b...
finance.yahoo.com - March 21 at 8:22 AM
Cramer Remix: Here's how Mark Zuckerberg should respond t...Cramer Remix: Here's how Mark Zuckerberg should respond t...
finance.yahoo.com - March 21 at 8:22 AM
Cramer: These charts show 'signs of life' for biotechCramer: These charts show 'signs of life' for biotech
finance.yahoo.com - March 21 at 8:22 AM
Try This ETF Pair To Round Out Your Biotech Exposure - Seeking AlphaTry This ETF Pair To Round Out Your Biotech Exposure - Seeking Alpha
seekingalpha.com - March 16 at 8:05 AM
In The Spotlight: Biohaven Pharma - NasdaqIn The Spotlight: Biohaven Pharma - Nasdaq
www.nasdaq.com - March 7 at 8:04 AM
M&R Capital Management Inc. Grows Position in iShares NASDAQ Biotechnology Index (IBB)M&R Capital Management Inc. Grows Position in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - March 6 at 2:58 PM
Scotia Capital Inc. Has $8.40 Million Stake in iShares NASDAQ Biotechnology Index (IBB)Scotia Capital Inc. Has $8.40 Million Stake in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - March 6 at 2:17 PM
Stock Market News for March 5, 2018 - NasdaqStock Market News for March 5, 2018 - Nasdaq
www.nasdaq.com - March 6 at 8:04 AM
iShares NASDAQ Biotechnology Index (IBB) Holdings Lifted by Eaton Vance ManagementiShares NASDAQ Biotechnology Index (IBB) Holdings Lifted by Eaton Vance Management
www.americanbankingnews.com - March 5 at 10:58 AM
iShares NASDAQ Biotechnology Index (IBB) Position Decreased by Lombard Odier Asset Management Switzerland SAiShares NASDAQ Biotechnology Index (IBB) Position Decreased by Lombard Odier Asset Management Switzerland SA
www.americanbankingnews.com - March 4 at 2:39 PM
Calamos Advisors LLC Grows Position in iShares NASDAQ Biotechnology Index (IBB)Calamos Advisors LLC Grows Position in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - March 2 at 5:19 AM
Sorry Celgene. Bigger Isn’t Better in Biotech.Sorry Celgene. Bigger Isn’t Better in Biotech.
www.barrons.com - March 1 at 6:01 PM
In The Spotlight: ARMO BioSciences - NasdaqIn The Spotlight: ARMO BioSciences - Nasdaq
www.nasdaq.com - March 1 at 8:04 AM
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by CLS Investments LLCiShares NASDAQ Biotechnology Index (IBB) Shares Bought by CLS Investments LLC
www.americanbankingnews.com - February 28 at 1:47 PM
Tetraphase Pharmaceuticals Trial Failure May Mask Value - Seeking AlphaTetraphase Pharmaceuticals Trial Failure May Mask Value - Seeking Alpha
seekingalpha.com - February 28 at 8:04 AM
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Brown Advisory Inc.iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Brown Advisory Inc.
www.americanbankingnews.com - February 28 at 5:14 AM
iShares NASDAQ Biotechnology Index (IBB) Holdings Boosted by Ashfield Capital Partners LLCiShares NASDAQ Biotechnology Index (IBB) Holdings Boosted by Ashfield Capital Partners LLC
www.americanbankingnews.com - February 28 at 4:46 AM
Suntrust Banks Inc. Has $3.43 Million Position in iShares NASDAQ Biotechnology Index (IBB)Suntrust Banks Inc. Has $3.43 Million Position in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 27 at 4:26 PM
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Clal Insurance Enterprises Holdings LtdiShares NASDAQ Biotechnology Index (IBB) Shares Bought by Clal Insurance Enterprises Holdings Ltd
www.americanbankingnews.com - February 27 at 3:37 PM
Commerce Bank Has $84.70 Million Holdings in iShares NASDAQ Biotechnology Index (IBB)Commerce Bank Has $84.70 Million Holdings in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 27 at 9:34 AM

SEC Filings

Ishares Nasdaq Biotechnology (NASDAQ:IBB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ishares Nasdaq Biotechnology (NASDAQ:IBB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ishares Nasdaq Biotechnology (NASDAQ IBB) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.